A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-001 in Subjects With Metastatic or Locally-advanced Solid Tumors
Latest Information Update: 23 Jul 2021
At a glance
- Drugs Danburstotug (Primary)
- Indications Advanced breast cancer; Biliary cancer; Chondrosarcoma; Colorectal cancer; Gastric cancer; Malignant thymoma; Solid tumours; Synovial sarcoma; Thyroid cancer
- Focus Adverse reactions; First in man
- Sponsors ImmuneOncia Therapeutics
- 16 Jul 2021 Results published in the Investigational New Drugs
- 22 Apr 2020 Status changed from active, no longer recruiting to completed, according to an Samsung BioLogics, ImmuneOncia Therapeutics Inc. media release.
- 15 Apr 2019 Status changed from recruiting to active, no longer recruiting.